Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal

Pfizer partnered with Germany’s Merck KGAA to develop and commercialize an anti-PD-L1 checkpoint inhibitor in clinical development, paying $850 million upfront to catch up to the competition.